434 related articles for article (PubMed ID: 22690069)
1. Leaky gut and the liver: a role for bacterial translocation in nonalcoholic steatohepatitis.
Ilan Y
World J Gastroenterol; 2012 Jun; 18(21):2609-18. PubMed ID: 22690069
[TBL] [Abstract][Full Text] [Related]
2. Role of gut microbiota and Toll-like receptors in nonalcoholic fatty liver disease.
Miura K; Ohnishi H
World J Gastroenterol; 2014 Jun; 20(23):7381-91. PubMed ID: 24966608
[TBL] [Abstract][Full Text] [Related]
3. FXR modulates the gut-vascular barrier by regulating the entry sites for bacterial translocation in experimental cirrhosis.
Sorribas M; Jakob MO; Yilmaz B; Li H; Stutz D; Noser Y; de Gottardi A; Moghadamrad S; Hassan M; Albillos A; Francés R; Juanola O; Spadoni I; Rescigno M; Wiest R
J Hepatol; 2019 Dec; 71(6):1126-1140. PubMed ID: 31295531
[TBL] [Abstract][Full Text] [Related]
4. Role of non-steroidal anti-inflammatory drugs on intestinal permeability and nonalcoholic fatty liver disease.
Utzeri E; Usai P
World J Gastroenterol; 2017 Jun; 23(22):3954-3963. PubMed ID: 28652650
[TBL] [Abstract][Full Text] [Related]
5. The role of the gut microbiota in nonalcoholic fatty liver disease.
Abu-Shanab A; Quigley EM
Nat Rev Gastroenterol Hepatol; 2010 Dec; 7(12):691-701. PubMed ID: 21045794
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological activation of REV-ERBα improves nonalcoholic steatohepatitis by regulating intestinal permeability.
Ni Y; Zhao Y; Ma L; Wang Z; Ni L; Hu L; Fu Z
Metabolism; 2021 Jan; 114():154409. PubMed ID: 33096076
[TBL] [Abstract][Full Text] [Related]
7. Microbiota-driven gut vascular barrier disruption is a prerequisite for non-alcoholic steatohepatitis development.
Mouries J; Brescia P; Silvestri A; Spadoni I; Sorribas M; Wiest R; Mileti E; Galbiati M; Invernizzi P; Adorini L; Penna G; Rescigno M
J Hepatol; 2019 Dec; 71(6):1216-1228. PubMed ID: 31419514
[TBL] [Abstract][Full Text] [Related]
8. The role of gut-liver axis in the pathogenesis of liver cirrhosis and portal hypertension.
Seo YS; Shah VH
Clin Mol Hepatol; 2012 Dec; 18(4):337-46. PubMed ID: 23323248
[TBL] [Abstract][Full Text] [Related]
9. Innate immune reactivity of the ileum-liver axis in nonalcoholic steatohepatitis.
Tsujimoto T; Kawaratani H; Kitazawa T; Uemura M; Fukui H
Dig Dis Sci; 2012 May; 57(5):1144-51. PubMed ID: 22367065
[TBL] [Abstract][Full Text] [Related]
10. Gut-liver axis signaling in portal hypertension.
Simbrunner B; Mandorfer M; Trauner M; Reiberger T
World J Gastroenterol; 2019 Oct; 25(39):5897-5917. PubMed ID: 31660028
[TBL] [Abstract][Full Text] [Related]
11. Intestinal permeability changes with bacterial translocation as key events modulating systemic host immune response to SARS-CoV-2: A working hypothesis.
Cardinale V; Capurso G; Ianiro G; Gasbarrini A; Arcidiacono PG; Alvaro D
Dig Liver Dis; 2020 Dec; 52(12):1383-1389. PubMed ID: 33023827
[TBL] [Abstract][Full Text] [Related]
12. Differences in Bacterial Translocation and Liver Injury in Ethanol Versus Diet-Induced Liver Disease.
Hsu CL; Wang Y; Duan Y; Chu H; Hartmann P; Llorente C; Zhou R; Schnabl B
Dig Dis Sci; 2023 Jul; 68(7):3059-3069. PubMed ID: 36807831
[TBL] [Abstract][Full Text] [Related]
13. Beneficial Effect of Synbiotic Supplementation on Hepatic Steatosis and Anthropometric Parameters, But Not on Gut Permeability in a Population with Nonalcoholic Steatohepatitis.
Ferolla SM; Couto CA; Costa-Silva L; Armiliato GN; Pereira CA; Martins FS; Ferrari Mde L; Vilela EG; Torres HO; Cunha AS; Ferrari TC
Nutrients; 2016 Jun; 8(7):. PubMed ID: 27367724
[TBL] [Abstract][Full Text] [Related]
14. Nonalcoholic fatty liver disease: for better or worse, blame the gut microbiota?
Li DY; Yang M; Edwards S; Ye SQ
JPEN J Parenter Enteral Nutr; 2013 Nov; 37(6):787-93. PubMed ID: 23538296
[TBL] [Abstract][Full Text] [Related]
15. Enteric Pathogens and Their Toxin-Induced Disruption of the Intestinal Barrier through Alteration of Tight Junctions in Chickens.
Awad WA; Hess C; Hess M
Toxins (Basel); 2017 Feb; 9(2):. PubMed ID: 28208612
[TBL] [Abstract][Full Text] [Related]
16. Contribution of the Intestinal Microbiome and Gut Barrier to Hepatic Disorders.
Chopyk DM; Grakoui A
Gastroenterology; 2020 Sep; 159(3):849-863. PubMed ID: 32569766
[TBL] [Abstract][Full Text] [Related]
17. Gut-liver axis, cirrhosis and portal hypertension: the chicken and the egg.
Arab JP; Martin-Mateos RM; Shah VH
Hepatol Int; 2018 Feb; 12(Suppl 1):24-33. PubMed ID: 28550391
[TBL] [Abstract][Full Text] [Related]
18. Gut-liver axis and fibrosis in nonalcoholic fatty liver disease: an input for novel therapies.
Frasinariu OE; Ceccarelli S; Alisi A; Moraru E; Nobili V
Dig Liver Dis; 2013 Jul; 45(7):543-51. PubMed ID: 23280158
[TBL] [Abstract][Full Text] [Related]
19. Microbiota and gut-liver axis: their influences on obesity and obesity-related liver disease.
Vajro P; Paolella G; Fasano A
J Pediatr Gastroenterol Nutr; 2013 May; 56(5):461-8. PubMed ID: 23287807
[TBL] [Abstract][Full Text] [Related]
20. The role of intestinal bacteria overgrowth in obesity-related nonalcoholic fatty liver disease.
Ferolla SM; Armiliato GN; Couto CA; Ferrari TC
Nutrients; 2014 Dec; 6(12):5583-99. PubMed ID: 25479248
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
